First AD

Second AD

Treatment Response to PPAR Agonists and Other Therapies in PBC

Video content above is prompted by the following:

How do you determine if treatment is effective in PBC?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

Expanding Treatment Options for Primary Biliary Cholangitis with Novel Therapies

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by the progressive destruction of small and medium-sized bile ducts within the liver. This destruction is primarily mediated by autoreactive T lymphocytes targeting the epithelial cells of the bile ducts. The ensuing cholestasis leads to the accumulation of toxic bile acids, causing hepatocellular damage and inflammation. Over time, this chronic inflammatory process results in fibrosis and eventually cirrhosis. The pathophysiology of PBC is influenced by genetic predispositions and environmental factors, contributing to its complex etiology and progression.

The panel of experts discuss how to determine the effectiveness of treatment in primary biliary cholangitis (PBC), focusing on key clinical markers, biochemical responses, and patient outcomes.